Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what?
about
Cancer Stem Cells: The Potential Targets of Chinese Medicines and Their Active CompoundsMinimal residual disease in breast cancer: an overview of circulating and disseminated tumour cellsPrediction of Cancer Drug Resistance and Implications for Personalized MedicineChemoresistance, cancer stem cells, and miRNA influences: the case for neuroblastomaChemoquiescence for ideal cancer treatment and prevention: where are we now?Life history trade-offs in cancer evolutionStress granule-associated protein G3BP2 regulates breast tumor initiation.In vivo models in breast cancer research: progress, challenges and future directions.MEK inhibition as a strategy for targeting residual breast cancer cells with low DUSP4 expression.Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance.Transient TNF regulates the self-renewing capacity of stem-like label-retaining cells in sphere and skin equivalent models of melanoma.Clinical observations on chemotherapy curable malignancies: unique genetic events, frozen development and enduring apoptotic potential.ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat.Curcumin Improves the Tumoricidal Effect of Mitomycin C by Suppressing ABCG2 Expression in Stem Cell-Like Breast Cancer Cells.Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer.Application of fluorescent dye substrates for functional characterization of ABC multidrug transporters at a single cell level.Mechanisms of Cancer Cell Dormancy--Another Hallmark of Cancer?Metabolic phenotyping for monitoring ovarian cancer patients.FOXC2 regulates the G2/M transition of stem cell-rich breast cancer cells and sensitizes them to PLK1 inhibition.Breast cancer cells evade paclitaxel-induced cell death by developing resistance to dasatinib.Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells.Bitter melon extracts enhance the activity of chemotherapeutic agents through the modulation of multiple drug resistance.Reverse the Resistance to PARP Inhibitors.Understanding resistance to combination chemotherapy.Resistance to PARP-Inhibitors in Cancer Therapy.Effect of atmospheric gas plasmas on cancer cell signaling.Nanocarrier-mediated drugs targeting cancer stem cells: an emerging delivery approach."Drug resistance associated membrane proteins".Mechanisms and therapeutic potential of inhibiting drug efflux transporters.Proteomic approach to understand metastatic spread.Synthesis and SAR Study of Anticancer Protoflavone Derivatives: Investigation of Cytotoxicity and Interaction with ABCB1 and ABCG2 Multidrug Efflux Transporters.A new model of multi-visceral and bone metastatic prostate cancer with perivascular niche targeting by a novel endothelial specific adenoviral vector.Cancer Drug Resistance: A Brief Overview from a Genetic Viewpoint.Roles of different IRES-dependent FGF2 isoforms in the acquisition of the major aggressive features of human metastatic melanoma.Intrinsic TGF-β2-triggered SDF-1-CXCR4 signaling axis is crucial for drug resistance and a slow-cycling state in bone marrow-disseminated tumor cells.Anti-Cancer Phytometabolites Targeting Cancer Stem CellsThe use of natural products to target cancer stem cells.Pharmacological Development of Target-Specific Delocalized Lipophilic Cation-Functionalized Carboranes for Cancer Therapy.Dual pharmacological inhibition of glutathione and thioredoxin systems synergizes to kill colorectal carcinoma stem cells.Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer.
P2860
Q26747518-16D9ED2E-0D15-49A7-BB2B-2415E672D731Q26748850-7ABB699B-1F23-4F05-81C7-3265DC1E1A49Q26770581-CF1852E6-06C6-4383-96BD-50EE0B2C4672Q26800007-B6589A33-9AE9-4693-B114-33A6DCDEDB32Q27026391-6E7A2226-3158-4E3A-A6D7-0D8ACB82C44CQ28657962-1D47DC2D-9D5C-4005-90AC-5DBA755F4C5CQ30008789-32864EE1-1DF2-452B-8F18-35A9E02D7318Q33588117-B28C0258-38FD-4710-AA6D-050488EAC264Q33739330-E20C15EB-E4E7-48C6-B21D-24065693EB08Q33763765-043BB3A5-BC04-4F5F-ACC4-0DE14758CC2CQ34233871-7FC1FB9C-699B-4EE2-BC16-050452A8DBB5Q35021459-C75B09F1-7BA2-4B04-9B32-C880759124A5Q35695410-CA49526E-F393-4C52-94EA-AA84FEF2D991Q35754947-63A64262-53C5-4AC8-B6A9-FEF05D33DDA6Q35845827-B2813AFB-7EE0-4325-BB8A-0419ED135A5FQ36125117-FB968EB4-65D1-4444-A323-0EEA717716B5Q36342849-31761B5B-BE7A-44A6-975A-584714D29C2CQ36708032-9A21D63F-D800-4B33-A429-A0712C96A845Q36786443-CB91A12B-4C0E-437B-B080-F83876CE2E49Q37205970-7A81BAE3-F992-4A3C-A227-6B36067F196DQ37214346-15EEBD2E-5D12-499E-84A3-AE500AD9BAD8Q37610933-A1632F7A-4D7F-4FD1-B43C-38A99CED9512Q37675896-2189263B-12A7-4EE2-9E44-DC57211BB4D4Q38060916-EF97F4C5-91C1-4467-B4E1-86D3428D330EQ38085600-ED868A6B-6021-4832-A98A-C05A53348AC7Q38113502-D5F746B8-D8F1-4145-A864-7D7894CEB443Q38324456-67016155-7934-49C2-A811-89A23DE1F987Q38366599-E814D574-99CE-43A1-80A9-4DB1E79786A3Q38388828-FE9F5AD7-893D-4CF6-8F2E-A824054273BAQ38443346-4EE1DF53-4280-490F-A1D9-0451688D0D10Q38706351-ABAE91C0-4265-455A-BB3A-D72D717801ABQ38720538-8F05F492-80E5-498C-99B2-35E4C7BEDF71Q38748101-EB28E64F-07FB-4335-9F98-EAB53D170A50Q38750311-6934C50D-1CDD-4A48-A3B0-FCDFC7BCD4B7Q38928700-131727B9-6ABC-41CF-8EC9-57664442D6C4Q39214227-F37020ED-5331-44B6-8E8F-D48C460A9E6CQ39458512-21C06C81-1747-4D7D-8F74-4E608F8921ACQ39820811-A8B9E6A1-C0EE-4495-A668-C50B2465DADFQ41368267-3D5F88F5-BD16-48D3-ADED-F78640CB5896Q41514180-FF99DC16-C8A1-4C0D-8ABE-023F263945A8
P2860
Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what?
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Cancer drug pan-resistance: pu ...... pathways, persisters or what?
@ast
Cancer drug pan-resistance: pu ...... pathways, persisters or what?
@en
type
label
Cancer drug pan-resistance: pu ...... pathways, persisters or what?
@ast
Cancer drug pan-resistance: pu ...... pathways, persisters or what?
@en
prefLabel
Cancer drug pan-resistance: pu ...... pathways, persisters or what?
@ast
Cancer drug pan-resistance: pu ...... pathways, persisters or what?
@en
P2860
P356
P1433
P1476
Cancer drug pan-resistance: pu ...... pathways, persisters or what?
@en
P2093
Piet Borst
P2860
P304
P356
10.1098/RSOB.120066
P577
2012-05-01T00:00:00Z